[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555404":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":328,"collaborators":330,"id":336,"slug":337,"hasResults":338,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":338,"sex":344,"minAge":345,"maxAge":25,"enrollmentInfo":346,"targetDuration":25,"studyType":349,"phases":350,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":366},{"fullName":5,"class":6},"Spanish Oncology Genito-Urinary Group","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Erdafitinib (ERDA) monotherapy","EXPERIMENTAL","Patients will receive treatment neoadjuvant with erdafitinib alone (cohort 1: Erdafitinib) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment)",[13],"Drug: Erdafitinib monotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Erdafitinib (ERDA) and Cetrelimab (CET) combination","Patients will receive treatment neoadjuvant with erdafitinib + cetrelimab (cohort 2: Erdafitinib + Cetrelimab) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment)",[18],"Drug: Cetrelimab and Erdafitinib combination",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Erdafitinib monotherapy","Patients will receive treatment with erdafitinib alone (cohort 1)",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Cetrelimab and Erdafitinib combination","Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Isabel Grau","CONTACT","0034610286915","trialmanager@sogug.es",[37,54,64,77,90,103,118,127,140,157,167,182,196,207,220,233,246,259,272,283,296,306,315],{"facility":38,"status":39,"city":40,"state":25,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"CLCC Jean Perrin","RECRUITING","Clermont-Ferrand","63011","France","FR",{"type":45,"coordinates":46},"Point",[47,48],3.08682,45.77969,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":25,"phoneExt":25,"email":53},"Hakim Mahammedi, MD and PhD","hakim.mahammedi@clermont.unicancer.fr",{"facility":55,"status":56,"city":57,"state":25,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":25},"CLCC Léon Bérard","WITHDRAWN","Lyon","69008",{"type":45,"coordinates":60},[61,62],4.84789,45.74906,{"lat":62,"lon":61},{"facility":65,"status":39,"city":66,"state":25,"zip":67,"country":42,"countryCode":43,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Institut Mutualiste Montsouris","Paris","75014",{"type":45,"coordinates":69},[70,71],2.3488,48.85341,{"lat":71,"lon":70},[74],{"name":75,"role":33,"phone":25,"phoneExt":25,"email":76},"Marie-Liesse Joulia, MD, PhD","marie-liesse.joulia@imm.fr",{"facility":78,"status":39,"city":79,"state":25,"zip":80,"country":42,"countryCode":43,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"IUCT","Toulouse","31059",{"type":45,"coordinates":82},[83,84],1.44367,43.60426,{"lat":84,"lon":83},[87],{"name":88,"role":33,"phone":25,"phoneExt":25,"email":89},"Damien Poussel, MD, PhD","pouessel.damien@iuct-oncopole.fr",{"facility":91,"status":39,"city":92,"state":25,"zip":93,"country":42,"countryCode":43,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Institut Gustave Roussy","Villejuif","94805",{"type":45,"coordinates":95},[96,97],2.35992,48.7939,{"lat":97,"lon":96},[100],{"name":101,"role":33,"phone":25,"phoneExt":25,"email":102},"Yohann Loriot, MD, PhD","Yohann.LORIOT@gustaveroussy.fr",{"facility":104,"status":39,"city":105,"state":25,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"IRCCS San Raffaele Hospital and Scientific Institute","Milan","20132","Italy","IT",{"type":45,"coordinates":110},[111,112],9.18951,45.46427,{"lat":112,"lon":111},[115],{"name":116,"role":33,"phone":25,"phoneExt":25,"email":117},"Andrea Necchi, MD, PhD","necchi.andrea@hsr.it",{"facility":119,"status":56,"city":120,"state":25,"zip":121,"country":107,"countryCode":108,"cosmosGeoPoint":122,"geoPoint":126,"contacts":25},"A.O. Ordine Mauriziano, Ospedale Umberto I","Turi","10128",{"type":45,"coordinates":123},[124,125],17.02038,40.91657,{"lat":125,"lon":124},{"facility":128,"status":39,"city":129,"state":25,"zip":130,"country":107,"countryCode":108,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Ospedale Molinette","Turin","10126",{"type":45,"coordinates":132},[133,134],7.68682,45.07049,{"lat":134,"lon":133},[137],{"name":138,"role":33,"phone":25,"phoneExt":25,"email":139},"Paolo Gontero, MD, PhD","paolo.gontero@unito.it",{"facility":141,"status":39,"city":142,"state":143,"zip":144,"country":145,"countryCode":146,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Hospital Clínic De Barcelona","Barcelona","Catalonia","08036","Spain","ES",{"type":45,"coordinates":148},[149,150],2.15899,41.38879,{"lat":150,"lon":149},[153,155],{"name":154,"role":33,"phone":25,"phoneExt":25,"email":25},"Oscar Reig, MD, PhD.",{"name":156,"role":33,"phone":25,"phoneExt":25,"email":25},"OREIG@clinic.cat",{"facility":158,"status":39,"city":142,"state":143,"zip":159,"country":145,"countryCode":146,"cosmosGeoPoint":160,"geoPoint":162,"contacts":163},"Hospital De Sabadell (Parc Taulí)","08208",{"type":45,"coordinates":161},[149,150],{"lat":150,"lon":149},[164],{"name":165,"role":33,"phone":25,"phoneExt":25,"email":166},"Teresa Bonfill, MD, PhD.","TBonfill@tauli.cat",{"facility":168,"status":39,"city":169,"state":170,"zip":171,"country":145,"countryCode":146,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Complexo Hospitalario Universitario A Coruña","A Coruña","Galicia","15006",{"type":45,"coordinates":173},[174,175],-8.396,43.37135,{"lat":175,"lon":174},[178,180],{"name":179,"role":33,"phone":25,"phoneExt":25,"email":25},"Aurea Molina, MD, PhD",{"name":25,"role":33,"phone":25,"phoneExt":25,"email":181},"aurea.molina.diaz@sergas.es",{"facility":183,"status":39,"city":184,"state":170,"zip":185,"country":145,"countryCode":146,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"Hospital Universitario Lucus Augusti","Lugo","27003",{"type":45,"coordinates":187},[188,189],-7.55602,43.00992,{"lat":189,"lon":188},[192,194],{"name":193,"role":33,"phone":25,"phoneExt":25,"email":25},"Sergio Vázque, MD, PhD",{"name":25,"role":33,"phone":25,"phoneExt":25,"email":195},"sergio.vazquez.estevez@sergas.es",{"facility":197,"status":198,"city":142,"state":25,"zip":199,"country":145,"countryCode":146,"cosmosGeoPoint":200,"geoPoint":202,"contacts":203},"ICO l' Hospitalet","NOT_YET_RECRUITING","08908",{"type":45,"coordinates":201},[149,150],{"lat":150,"lon":149},[204],{"name":205,"role":33,"phone":25,"phoneExt":25,"email":206},"Irene Ortiz Rubio, MD, PhD","ireneortiz@iconcologia.net",{"facility":208,"status":39,"city":209,"state":25,"zip":210,"country":145,"countryCode":146,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Hospital Universitario 12 de Octubre","Madrid","28041",{"type":45,"coordinates":212},[213,214],-3.70256,40.4165,{"lat":214,"lon":213},[217],{"name":218,"role":33,"phone":25,"phoneExt":25,"email":219},"Guillermo De Velasco, MD, PhD","guillermoantonio.velasco@salud.madrid.org",{"facility":221,"status":39,"city":222,"state":25,"zip":223,"country":145,"countryCode":146,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Hospital Universitario de Toledo","Toledo","45007",{"type":45,"coordinates":225},[226,227],-4.02263,39.8581,{"lat":227,"lon":226},[230],{"name":231,"role":33,"phone":25,"phoneExt":25,"email":232},"Iciar García Carbonero, MD, PhD","igcarbonero@yahoo.es",{"facility":234,"status":39,"city":235,"state":25,"zip":236,"country":145,"countryCode":146,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"Fundación Instituto Valenciano De Oncología","Valencia","46009",{"type":45,"coordinates":238},[239,240],-0.37966,39.47391,{"lat":240,"lon":239},[243],{"name":244,"role":33,"phone":25,"phoneExt":25,"email":245},"Maria José Juan, MD, Phd","mjuanfi81@hotmail.com",{"facility":247,"status":39,"city":248,"state":25,"zip":249,"country":145,"countryCode":146,"cosmosGeoPoint":250,"geoPoint":254,"contacts":255},"Hospital Clínico Universitario De Valladolid","Valladolid","47003",{"type":45,"coordinates":251},[252,253],-4.72353,41.65541,{"lat":253,"lon":252},[256],{"name":257,"role":33,"phone":25,"phoneExt":25,"email":258},"Ricardo Sánchez-Escribano, MD, PhD","rsescribano@seom.org",{"facility":260,"status":39,"city":261,"state":25,"zip":262,"country":145,"countryCode":146,"cosmosGeoPoint":263,"geoPoint":267,"contacts":268},"Hospital Universitario Miguel Servet","Zaragoza","50009",{"type":45,"coordinates":264},[265,266],-0.87734,41.65606,{"lat":266,"lon":265},[269],{"name":270,"role":33,"phone":25,"phoneExt":25,"email":271},"Carmen Santander Lobera, MD, PhD","csantlob@yahoo.es",{"facility":273,"status":56,"city":274,"state":25,"zip":275,"country":276,"countryCode":277,"cosmosGeoPoint":278,"geoPoint":282,"contacts":25},"University Hospitals of Morecambe Bay NHS Foundation Trust","Lancaster","LA1 4RP","United Kingdom","UK",{"type":45,"coordinates":279},[280,281],-2.79988,54.04649,{"lat":281,"lon":280},{"facility":284,"status":39,"city":285,"state":25,"zip":286,"country":276,"countryCode":277,"cosmosGeoPoint":287,"geoPoint":291,"contacts":292},"The Royal Marsden NHS Foundation Trust","London","SW3 6JJ",{"type":45,"coordinates":288},[289,290],-0.12574,51.50853,{"lat":290,"lon":289},[293],{"name":294,"role":33,"phone":25,"phoneExt":25,"email":295},"Vincent Khoo, MD, PhD","VincentPA.Khoo@rmh.nhs.uk",{"facility":297,"status":39,"city":285,"state":25,"zip":298,"country":276,"countryCode":277,"cosmosGeoPoint":299,"geoPoint":301,"contacts":302},"Barts Health NHS Trust","W6 8JA",{"type":45,"coordinates":300},[289,290],{"lat":290,"lon":289},[303],{"name":304,"role":33,"phone":25,"phoneExt":25,"email":305},"Tomas Powles, MD, PhD","thomas.powles1@nhs.net",{"facility":307,"status":39,"city":285,"state":25,"zip":25,"country":276,"countryCode":277,"cosmosGeoPoint":308,"geoPoint":310,"contacts":311},"Charing Cross Hospital",{"type":45,"coordinates":309},[289,290],{"lat":290,"lon":289},[312],{"name":313,"role":33,"phone":25,"phoneExt":25,"email":314},"Naveed Sarwar, MD, PhD","naveed.sarwar1@nhs.net",{"facility":316,"status":39,"city":317,"state":25,"zip":318,"country":276,"countryCode":277,"cosmosGeoPoint":319,"geoPoint":323,"contacts":324},"Sheffield Teaching Hospitals NHS Foundation Trust","Sheffield","S10 2SJ",{"type":45,"coordinates":320},[321,322],-1.4659,53.38297,{"lat":322,"lon":321},[325],{"name":326,"role":33,"phone":25,"phoneExt":25,"email":327},"Syed Hussain, MD, PhD","syed.hussain@sheffield.ac.uk",{"type":329,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[331,334],{"name":332,"class":333},"Janssen-Cilag Ltd.","INDUSTRY",{"name":335,"class":333},"Pivotal S.L.","100555404","phase-2-erdafitinib-monotherapy-or-in-combination-with-cetrelimab-in-muscle-invasive-bladder-cancer-patients-with-fibroblast-growth-factor-receptor-fgfr--gene-alterations-100555404",false,"NCT06511648","Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations","A Phase 2, Open-label, Multi-centre, Multi-national Interventional Trial to Evaluate the Efficacy and Safety of Erdafitinib (ERDA) Monotherapy and Erdafitinib (ERDA) and Cetrelimab (CET) Combination as Neoadjuvant Treatment in Cisplatin-ineligible Patients With Muscle-invasive Bladder Cancer (MIBC) Whose Tumours Express Fibroblast Growth Factor Receptor ( FGFR ) Gene Alterations","SOGUG-NEOWIN","Inclusion Criteria:\n\n1. Written informed consent stating that he or she understands the purpose of the study and the procedures involved and agrees to participate in the study.\n2. Histologically confirmed diagnosis of MIBC (Stage T2-4a N0\u002FN1 M0) obtained via a diagnostic or maximal Transurethral Resection of Bladder Tumor (TURBT) performed no later than 3 months prior to start the screening visit.\n3. Pure or predominant (≥50%) urotelial Cancer (UC) histology as determined at the local site.\n4. Age ≥ 18 years.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n6. Decline or ineligible (\"unfit\") for cisplatin-based chemotherapy\n7. Presence of a selected FGFR alteration on analysis of tumour biopsy\n8. Adequate organ function\n9. No other malignancy\n10. Willingness to avoid pregnancy or fathering children\n\nExclusion Criteria:\n\n1. Clinical evidence of N2-N3 tumours or metastatic bladder cancer.\n2. Has tumour with any neuroendocrine or small cell component.\n3. Patients who are not considered fit for cystectomy or reject cystectomy.\n4. Prior FGFR-targeted or an immune checkpoint inhibitor (antiPD1\u002FPDL1 )systemic therapy.\n5. Prior systemic therapy, radiation therapy, or surgery for bladder cancer","ALL","18 Years",{"count":347,"type":348},90,"ESTIMATED","INTERVENTIONAL",[351],"PHASE2","Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express Fibroblast Growth Factor Receptor (FGFR )gene alterations and are ineligible for or refuse cisplatin based neoadjuvant chemotherapy.",[354],"Muscle-invasive Bladder Cancer",[356],"Urothelial carcinoma","2025-12-12",{"date":359,"type":360},"2025-12-19","ACTUAL",{"date":362,"type":360},"2023-03-07",{"date":364,"type":348},"2029-10",{"name":5,"class":6},23]